

Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
12 - 14 April 2016
Centre International de Conférences Genève (CICG), Geneva

Tuesday, 12 April 2016

Time	Session	Purpose of session, target outcomes and questions for SAGE	
8:30	Welcome – introduction of participants J. Abramson, Chair of SAGE.		20 min.
8:50	Report from Director, IVB - Session 1 Global report including key updates and challenges from regions. J.-M. Okwo-Bele, WHO. 30 min. Discussion. 1h 30 min.	FOR INFORMATION	2h
10:15	Coffee/tea break	Break	30 min.
10:45	Report from Director, IVB - Session 1, contd. Discussion contd.		
11:20	Report from Gavi, the Vaccine Alliance - Session 2 Report from Gavi, the Vaccine Alliance. S. Berkley, Gavi, the Vaccine Alliance. 20 min. Discussion. 20 min.	FOR INFORMATION	40 min.
12:00	Reports from other Advisory Committees on Immunization - Session 3 Report of the Global Advisory Committee on Vaccine Safety (GACVS). R. Pless, Chair of GACVS. 10 min. Discussion. 10 min.	FOR INFORMATION	20 min.
12:20	Lunch	Break	1h 30 min.

13:50	Respiratory Syncytial Virus Vaccines (RSV) - Session 4 Summary of global epidemiology and disease burden estimates for RSV. H. Nair, University of Edinburgh. 10 min. Discussion. 10 min. Background to RSV active/passive immunization development, and status of leading candidates. R. Karron, Johns Hopkins Bloomberg School of Public Health. 20 min. Discussion. 20 min. WHO consultations in 2015-2016 on RSV active/passive immunization. V. Moorthy, WHO. 15 min. Discussion. 15 min.	FOR INFORMATION Update SAGE on the current status of development of RSV vaccines. Give SAGE an opportunity for any input that the group would like to contribute at this stage of vaccine development, noting that one candidate is in Pivotal Phase 3, and the pipeline is very active.	1h 30 min.
15:20	Coffee/tea break	Break	30 min.
15:50	Global polio eradication initiative - Session 5 Objective of the session and overview of Global Polio Eradication Initiative. M. Zaffran, WHO. 20 min. Updates on implementation of OPV2 withdrawal. D. Chang-Blanc, WHO. 20 min. Discussion. 20 min. Report from SAGE Polio WG. Y. AL-Mazrou, Chair of the Polio WG. 20 min. <ul style="list-style-type: none"> o Summary of WG meeting o Future immunization policy: Issues, way forward Discussion. 70 min.	FOR INFORMATION AND DISCUSSION To update SAGE on the: <ul style="list-style-type: none"> • current status of the polio eradication program • status of implementation of OPV2 withdrawal • issues and timelines for discussions on future immunization policy after OPV withdrawal SAGE is asked to discuss the use of fractional ID IPV for campaign and routine immunization.	2h 30 min.
18:20	Cocktail		

Wednesday, 13 April 2016

08:30	Implementation in the context of health system strengthening (HSS) and universal health coverage- Session 6 <p>Introduction of the session. N. Turner, Member of SAGE. 5 min.</p> <p>Presentation on the role of HSS in achieving sustainable and effective impact including achieving economies of scale and improved quality and greater equity of coverage. M.-P. Kieny, WHO. 15 min.</p> <p>Questions for clarification. 15 min.</p> <p>Presentation of selected topics on implementation programme design including integrated supply chain management, quality data on service delivery and coordinated planning of services and examples of fragile states. H. Karamagi, WHO. 20 min.</p> <p>Discussion. 65 min.</p>	FOR INFORMATION AND DISCUSSION <p>Inform SAGE on adapting immunization services and provision to support integrated service delivery as part of the health system to achieve universal health coverage.</p> <p>The session will provide an overview of the health systems, complexity and immunization. It will address key experiences related to implementation of vaccines and financial efficiency and gains. Based on experience from Ebola, will highlight importance of resilience and lessons learnt.</p> <p>SAGE will be asked to provide feedback. This input will be used to define an operations research agenda on a systems based approach for improving immunization coverage and closing equity gaps..</p>	2h
10:30	Coffee/tea break	Break	30 min.
11:00	Preempting and responding to vaccine shortages - Session 7 <p>Introduction of the session. C-A. Siegrist, Member of SAGE. 15 min.</p> <p>Dealing with vaccine shortages: current situation and ongoing activities.</p> <ol style="list-style-type: none"> 1. Impact of shortages and solutions set up by countries. O. Benes. WHO. 15 min. 2. Vaccine shortages: Improving cooperation, communication and management in the European Union. M. Sulzner, European Commission Directorate-General for Health and Food Safety. 10 min. 3. Global operational procurement planning and long-term strategic supply security. A. Ottosen, UNICEF. 20 min. <p>Discussion. 60 min.</p>	FOR INFORMATION AND DISCUSSION <p>Present SAGE with a review of the current situation of vaccine shortages, reasons for shortages as well as elements that increase their risk.</p> <p>Present SAGE with activities that are already being put in place at the national, regional and global levels to mitigate the impact of shortages and pre-empt them.</p> <p>SAGE will be requested to provide guidance to WHO regarding activities that need to be continued, strengthened or explored to better pre-empt and respond to global shortages, particularly within the scope of the WHA68.6 resolution - conditional to the need for additional resources if further activities were to be implemented.</p>	2h
13:00	Lunch	Break	1h

14:00	Missed opportunities for vaccination - Session 8 Introduction to the topic. C. Wiysonge, Member of SAGE. 10 min. Results of two country missed opportunities for vaccination assessments in Africa. R. Mihigo, WHO. 15 min. Status of missed opportunities for vaccination assessments in the Americas. M. Velandia, WHO. 15 min. WHO Global Plan of Action for Improving Coverage and Equity by Scaling Up Missed Opportunities Interventions. I. Ogbuanu, WHO. 20 min. Discussion. 60 min.	FOR INFORMATION AND DECISION SAGE will be: <ul style="list-style-type: none"> • Provided with an update on ongoing work to address missed opportunities for vaccination • Presented with the potential value and impact of the updated approach for assessing extent of, and implementing solutions to reduce missed opportunities for vaccination • Requested to endorse the updated approach for reducing missed opportunities • Asked to advise on the proposed framework for addressing missed opportunities and on the partner coordination mechanisms 	2h
16:00	Coffee/tea break	Break	30 min.
16:30	Second year of life platform - Session 9 Introduction to the topic. J. Jawad, Member of SAGE. 10 min. Activities towards developing guidance for a Second-Year-of-Life (2YL) healthy child visit. R. Eggers, WHO. 15 min. Discussion. 30 min. Findings of the Zambia 2YL case study. R. Fields, John Snow, Inc.. 15 min. Landscape analysis on 2YL. I. Mirza, UNICEF. 15 min. Discussion. 30 min.	FOR INFORMATION AND DISCUSSION To inform SAGE and immunization partners about the development of guidance to establish a second year of life health child visit that includes vaccination. Aim is to inform SAGE on the justification for the needs and opportunities of a healthy child visit in the second year of life and provide an understanding of the proposed work and outcomes of this project. SAGE will be asked to provide input to the process and/or content.	2h
18:30	End of day		

Thursday, 14 April 2016

08:30	Dengue vaccine - Session 10 Introduction. J. Farrar, Wellcome Trust, Co-Chair of SAGE Working Group on Dengue vaccine. 15 min. Dengue vaccine clinical trial results. P. Smith, US Walter Reed Army Institute of Research. 30 min. Discussion. 20 min. Comparative modelling of dengue vaccine impact, N. Ferguson, Imperial College, London. 20 min. Discussion. 15 min.	FOR DECISION Present SAGE with the report of the SAGE Working Group on Dengue Vaccines and Vaccination on the CYD dengue vaccine and request SAGE's consideration of the proposed recommendations. SAGE recommendations on vaccine use will then be used to write the first WHO position paper on the use of a dengue vaccine.	3h
10:10	Coffee/tea break	Break	30 min.
10:40	Dengue vaccine - Session 10, contd. Dengue Vaccines Working Group assessment and proposed recommendations. T. Nolan, SAGE member and Co-Chair of SAGE Working Group on Dengue vaccine. 20 min. Discussion. 60 min.		
12:00	Closing		20 min.
12:20	End of meeting		